natgillin/translations-raw huggingface dataset:
Analyser af kardiotoksicitet ved kliniske forsøg har vist en statistisk signifikant reduktion af hjerte- sygdomme hos patienter behandlet med Myocet sammenlignet med patienter, behandlet med konventionelt doxorubicin på samme dosis i mg.
Analyses of cardiotoxicity in clinical trials have shown a statistically significant reduction in cardiac events in patients treated with Myocet compared to patients treated with conventional doxorubicin at the same dose in mg.
Analyser af kliniske studier
Analyses of Clinical Trials:
Analyser af multiple hændelser viste en risikoreduktion på 30,7 % i udviklingen af skeletrelaterede hændelser i zoledronsyre 4 mg-gruppen sammenlignet med placebo.
Multiple event analysis showed 30.7 % risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo.
Analyser af populationsfarmakokinetik tyder på, at sunitinibs tilsyneladende clearance (CL/F) ikke er påvirket af kreatininclearence inden for det vurderede område (42-347 ml/min).
Population pharmacokinetic analyses indicated that sunitinib apparent clearance (CL/F) was not affected by creatinine clearance within the range evaluated (42 - 347 ml/min).
Analyser af resultaterne for overvægtige patienter, behandlet med metformin, da diæt havde vist sig utilstrækkelig:
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:
Analyser fra registreringen skal indsendes årligt.
Analyses from the registry to be submitted annually
Analyser:
Analyses:
Analyserne af PFS, samlet responsrate (ORR, overall response rate) og lymfeknude responsrate (LNR, lymph node response rate) var baseretpå evalueringaf en uafhængig bedømmelseskomité (IRC, independentreview committee).
The analyses of PFS, overall response rate (ORR) and lymph node response rate (LNR) were based on evaluation by an independent review committee (IRC).
Analyserne af PFS, samlet responsrate (ORR, overall response rate) og lymfeknude- responsrate (LNR, lymph node response rate) var baseretpå evalueringforetagetaf en uafhængig bedømmelseskomité (IRC, independentreview committee).
The analyses of PFS, overall response rate (ORR) and lymph node response rate (LNR) were based on evaluation by an independent review committee (IRC).
Analysis Set, PPS), 4 seropositivitetsrater, 5 ingen immunogenicitetsprøver blev taget, 6 kombinerede grupper 1-3
4 seropositivity rates, 5 no immunogenicity sample taken, 6 combined Groups 1-3
Anamnese
Disease history
anamnese af hovedtraume
history of head trauma
Anamnese med allerede eksisterende alvorlig hjertesygdom, inklusive ustabil eller ukontrolleret hjertesygdom, i de foregående seks måneder (se pkt.
A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease, in the previous six months (see section 4.4).
Anamnese med anafylaktisk (dvs. livstruende) reaktion på et eller flere af indholdsstofferne eller sporstoffer (ægge- og kyllingeproteiner, ovalbumin, kanamycin- og neomycinsulfat, bariumsulfat, formaldehyd og cetyltrimethylammoniumbromid (CTAB)) i denne vaccine.
History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, barium sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB)) of this vaccine.
Anamnese med anafylaktisk (dvs. livstruende) reaktion på ethvert indholdsstof eller spor af æg, hønseproteiner, kanamycin og neomycinsulfat, bariumsulfat, formaldehyd og cetyltrimethyl- ammoniumbromid (CTAB) i denne vaccine.
History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues of eggs, chicken proteins, kanamycin and neomycin sulphate, barium sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB) of this vaccine.
Anamnese med anafylaktisk (dvs. livstruende) reaktion på ethvert indholdsstof eller spor af æg, hønseproteiner, kanamycin- og neomycinsulfat, bariumsulfat, formaldehyd og cetyltrimethylammoniumbromid (CTAB) i denne vaccine.
History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues of eggs, chicken proteins, kanamycin and neomycin sulphate, barium sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB) of this vaccine.
anamnese med apopleksi inden for 30 dage eller en hvilket som helst tidligere hjerneblødning
history of stroke within 30 days or any history of haemorrhagic stroke
Anamnese med bloddyskrasier, for eksempel knoglemarvshypoplasi, leukopeni, trombocytopeni eller signifikant anæmi.
Pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anaemia.
anamnese med blødningstendens
a history of bleeding diathesis
Anamnese med hjerteinsufficiens eller systolisk dysfunktion af venstre ventrikel
History of, or current heart failure or left ventricular systolic dysfunction
Anamnese med hjerteinsufficiens eller systolisk dysfunktion af venstre ventrikel.
History of, or current heart failure or left ventricular systolic dysfunction.
Anamnese med medfødt blødningsdiatese
history of congenital bleeding diatheses
Anamnese med påvist nuværende eller tidligere iskæmisk hjertesygdom, perifer arteriel sygdom og/eller cerebrovaskulær sygdom.
Established, current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
Anamnese med svært hovedtraume, som har krævet hospitalsindlæggelse, intrakraniel eller intraspinal operation, hæmoragisk apopleksi indenfor de seneste 3 måneder, enhver intracerebral arteriovenøs misdannelse, cerebral aneurisme eller solid svulst i centralnervesystemet eller patienter der har epiduralkateter eller som forventes at få lagt epiduralkateter under infusionen.
history of severe head trauma that required hospitalization, intracranial or intraspinal surgery, or haemorrhagic stroke within the previous 3 months, or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesion; patients with an epidural catheter or who are anticipated to receive an epidural catheter during drug infusion
Anamnese med symptomatiske kardiale arytmier eller med klinisk relevant bradykardi.
History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.
Anamnese og objektiv undersøgelse
History and physical examination
anamnestisk eller aktuel bradyarytmi
A history of or ongoing bradyarrhythmia;
anamnestisk eller aktuel hypotyroidisme
A history of or ongoing hypothyroidism;
Ananasjuice koncentrat Citronsyre, vandfri Naturlige smagsstoffer
Pineapple juice concentrate Citric acid anhydrous Natural flavouring
Anaphylaktisk reaktion
Diarrhoeaa Vomitinga Constipationa Nauseaa
anasarka (udbredt hævelse af hud)
anasarca (widespread swelling of the skin)
Anbe falinge r
Recommendations
Anbefalede baselineværdier for indledning af INCIVO-kombinationsbehandling:
These are recommended baseline values for initiation of INCIVO combination treatment:
Anbefalede doser og anbefalinger til dosering ved de forskellige indikationer
Recommended dosages and guidance on the posology for different indications
Anbefalede dosis modifikationer
Recommended dose modifications
Anbefalede dosisjusteringer
Recommended dose adjustments
Anbefalede dosisjusteringer af terapeutiske doser af enoxaparinnatrium
Recommended dose adjustments for therapeutic dose ranges of enoxaparin sodium
Anbefalede dosisjusteringer af terapeutiske dosisintervaller af enoxaparinnatrium
Recommended dose adjustments for therapeutic dose ranges of enoxaparin sodium
Anbefalede dosisjusteringer under behandlingen og genoptagelse af behandlingen
Recommended dose adjustments during treatment and restart of treatment:
Anbefalede dosisjusteringer, når enoxaparinnatrium bruges til behandling
Recommended dose adjustments for therapeutic dose ranges of enoxaparin sodium
Anbefalede dosisvoluminer er angivet i tabellen nedenfor:
Recommended dose volumes are given in the table below:
Anbefalede justeringer af dabrafenib-dosis
Recommended dabrafenib dose modifications
Anbefalede justeringer af trametinib-dosis
Recommended trametinib dose modifications
Anbefalede kontrolundersøgelser og sikkerhedsforanstaltninger
Recommended control examinations and safety precautions
Anbefalede modifikationer ved pancreatiske bivirkninger er opsummeret i tabel 2.
Recommended modifications for pancreatic adverse reactions are summarized in Table 2.
anbefalede rifabutindosis 150 mg
recommended dose of rifabutin
Anbefalede separationsafstande mellem bærbart og mobilt RF-kommunikationsudstyr og injektionssystemet
Recommended separation distances between portable and mobile RF communications equipment and the administration system
Anbefalede trin til dosisjustering under behandlingen og genoptagelse af behandlingen til håndtering af grad 3 eller 4 neutropeni eller trombocytopeni eller anden grad 3 eller 4 toksicitet, der vurderes som værende relateret til lenalidomid, som beskrevet ovenfor.
Recommended dose reduction steps during treatment and restart of treatment to manage grade 3 or 4 neutropenia or thrombocytopenia, or other grade 3 or 4 toxicity judged to be related to lenalidomide, as described above.
anbefales (se pkt.
(see section 4.4).
anbefales at separere administrationen af Vitekta og
recommended to separate Vitekta and antacid administration by at
anbefales derfor, at nyrefunktionen vurderes hos alle patienter før initiering af ribavirin.
Therefore, it is recommended that renal function be evaluated in all patients prior to initiation of ribavirin.
anbefales det ikke at drikke alkohol under behandling med Leflunomide Teva.
Therefore, it is not recommended to drink alcohol during treatment.
anbefales det, at EVOTAZ og
recommended that EVOTAZ and
anbefales dog.
It is not recommended to
anbefales for quinidin, når
for quinidine when
anbefales ikke (se pkt.
is not recommended (see
Anbefales ikke i kombination med en GnRH-agonist-protokol
Not recommended with a GnRH agonist protocol
Anbefales ikke til brug hos børn og unge.
Use in the paediatric patient population is not recommended.
Anbefales ikke til brug til børn og unge.
Use in children and adolescents is not recommended.
anbefales ikke til patienter
recommended in patients
Anbefales ikke, da RAVICTIs sikkerhed og virkning i denne aldersgruppe ikke er klarlagt.
Not recommended as the safety and efficacy of RAVICTI in this age group has not been established.
anbefales ikke, da voriconazol
is not recommended because
anbefales ikke.
boceprevir.
anbefales ikke.
It is not recommended to
anbefales ikke.
low dose ritonavir, is not
anbefales ikke.
not recommended.
anbefales og dosis af antikoa-
recommended, and the dose of
anbefales passende overvågning af INR.
international normalised ratio (INR) is recommended.
anbefales ved administration sammen med
is recommended when co-administered
anbefales, at
Careful monitoring of
anbefales, at plasmakoncen- trationer af phenytoin monitoreres omhyggeligt.
Careful monitoring of phenytoin plasma levels is recommended.
anbefales, hvis disse lægemidler
recommended when these medicinal
anbefales, når clarithromycin eller
is recommended when clarithromycin or
anbefales.
is recommended.
anbefales.
nifedipine
anbefales.
reactions.
anbefales.
recommended.
Anbefalet Aerinaze-dosis er 1 tablet 2 gange dagligt.
The recommended dose of Aerinaze is one tablet twice a day.
Anbefalet afstand fra behandlings- krævende væv
Recommended distance from target tissue
Anbefalet antal 100/25 mg tabletter 2 gange daglig
Recommended number of 100/25 mg tablets twice-daily
Anbefalet antal tabletter for hvert måltid
Recommended number of tablets at each meal
Anbefalet antal tabletter ved de enkelte måltider
Recommended number of tablets given at each meal
Anbefalet dosering - børn over 3 måneder og med en vægt på mindre end 25 kg:
Dosing recommendations – Children aged at least 3 months and weighing less than 25 kg:
Anbefalet dosering efter indikation
Recommended dose according to indication
Anbefalet dosering er 100 IU daglig eller 50 IU to gange daglig i 2-4 uger administreret subkutant eller intramuskulært.
The recommended dosage is 100 I.U. daily or 50 I.U. twice daily for 2 to 4 weeks, administered subcutaneously or intramuscularly.
Anbefalet dosering til voksne (inklusive ældre mennesker)
Recommended dosage in adults (including older people)
Anbefalet dosering – voksne, unge og børn (der vejer mindst 25 kg):
Dosing recommendations – Adults, adolescents and children (weighing at least 25 kg):
Anbefalet dosis af eribulin
Recommended dose of eribulin
Anbefalet dosis af Gazyvaro i kombination med bendamustin er 1000 mg administreret på 1. dag af hver 28-dages behandlingsserie.
The recommended dose of Gazyvaro in combination with bendamustine is 1,000 mg administered on Day 1 of each 28 day treatment cycle.
Anbefalet dosis af Gazyvaro i kombination med bendamustin er 1000 mg administreret på 1. dag, 8. dag og 15. dag i den første 28-dages behandlingsserie.
The recommended dose of Gazyvaro in combination with bendamustine is 1,000 mg administered on Day 1, Day 8 and Day 15 of the first 28 day treatment cycle.
Anbefalet dosis af MabThera subkutan formulering til voksne er en subkutan injektion i fast dosis på 1400 mg, uafhængigt af patientens legemsoverfladeareal.
The recommended dose of MabThera subcutaneous formulation used for adult patients is a subcutaneous injection at a fixed dose of 1400 mg irrespective of the patient’s body surface area.
Anbefalet dosis af MabThera subkutan formulering til voksne er en subkutan injektion i fast dosis på 1600 mg, uafhængigt af patientens legemsoverfladeareal.
The recommended dose of MabThera subcutaneous formulation used for adult patients is a subcutaneous injection at a fixed dose of 1600 mg irrespective of the patient’s body surface area.
Anbefalet dosis af Praxbind er 5 g (2 x 2,5 g/50 ml).
The recommended dose of Praxbind is 5 g (2x2.5 g/50 mL)
Anbefalet dosis af PREZISTA og ritonavira til ART-erfarne pædiatriske patienter
Recommended dose for treatment-experienced paediatric patients with PREZISTA and ritonavira
Anbefalet dosis af PREZISTA og ritonavira til behandlingsnaive pædiatriske patienter
Recommended dose for treatment-naïve paediatric patients with PREZISTA and ritonavira
Anbefalet dosis af PREZISTA tabletter og ritonavira til ART-erfarne pædiatriske patienter (3 til 17 år)
Recommended dose for treatment-experienced paediatric patients (3 to 17 years of age) for PREZISTA tablets and ritonavira
Anbefalet dosis af PREZISTA tabletter og ritonavira til behandlingserfarne pædiatriske patienter (3 til 17 år)
Recommended dose for treatment-experienced paediatric patients (3 to 17 years of age) for PREZISTA tablets and ritonavira
Anbefalet dosis af PREZISTA tabletter og ritonavira til behandlingsnaive pædiatriske patienter (3 til 17 år)
Recommended dose for treatment-naïve paediatric patients (3 to 17 years) with PREZISTA tablets and ritonavira
Anbefalet dosis af tafamidismeglumin er 20 mg oralt 1 gang dagligt.
The recommended dose of tafamidis meglumine is 20 mg orally once daily.
Anbefalet dosis af zoledronsyre*
Zoledronic acid recommended dose
Anbefalet dosis af Zometa*
Zometa recommended dose
Anbefalet dosis er 0,2-0,4 g/kg legemsvægt hver 3. til 4. uge.
The recommended dose is 0.2 - 0.4 g/kg every three to four weeks.
Anbefalet dosis er 0,2-0,4 g/kg legemsvægt hver 3. til 4. uge.
The recommended dose is 0.2-0.4 g/kg every three to four weeks.
Anbefalet dosis er 1 brev med 2 g én gang daglig per os.
The recommended dose is one 2 g sachet once daily by oral administration.
Anbefalet dosis er gentagne injektioner på 0,1-0,4 ml dispersion, efterfulgt af en 3-5 ml bolusdosis af natriumchlorid 9 mg/ml (0,9 %) eller glucose 50 mg/ml (5 %) opløsning til injektion for at opretholde en optimal kontrastforstærkning.
The recommended dose is multiple injections of 0.1 to 0.4 ml of dispersion, followed by a 3 to 5 ml bolus of sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solution for injection to maintain optimal contrast enhancement.
Anbefalet dosis for indledende behandling af akut DVT eller PE er 15 mg to gange dagligt i de første tre uger og derefter fortsat behandling og forebyggelse af recidiverende DVT og PE med 20 mg én gang dagligt som vist i nedenstående skema.
The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE, as indicated in the table below.
Anbefalet dosis i mg Hver 12. time
Recommended dose in mg Every 12 hours
Anbefalet dosis INTELENCE til pædiatriske patienter i alderen 6 år til yngre end 18 år
Recommended dose of INTELENCE for paediatric patients 6 years to less than 18 years of age
Anbefalet dosis og behandlingsvarighed
Recommended dose and duration
Anbefalet dosis og behandlingsvarighed for voksne
Recommended dose and duration of treatment for adults
Anbefalet dosis zoledronsyre*
Zoledronic Acid Recommended Dose
Anbefalet dosis* for ISENTRESS granulat til oral suspension og tyggetabletter til pædiatriske patienter, der vejer under 25 kg
Recommended Dose* for ISENTRESS Granules For Oral Suspension and Chewable Tablets in Paediatric Patients Weighing Less than 25 kg
Anbefalet dosis* for ISENTRESS tyggetabletter til pædiatriske patienter, der vejer under 25 kg
Recommended Dose* for ISENTRESS Chewable Tablets for Paediatric Patients Weighing at Least 25 kg
Anbefalet dosisa
Recommended dosea
Anbefalet dosismodifikation og foranstaltninger
Recommended dose modification and measures
Anbefalet dosisregime for Zerbaxa** (ceftolozan/tazobactam)**
Recommended dose regimen for Zerbaxa (ceftolozane/tazobactam)
Anbefalet fremgangsmåde for sikker håndtering
Recommendations for safe handling
Anbefalet initiale startdosis af Perjeta er 840 mg administreret som en 60 minutters intravenøs infusion, efterfulgt af en vedligeholdelsesdosis på 420 mg over 30 til 60 minutter hver 3. uge.
The recommended initial loading dose of Perjeta is 840 mg administered as a 60 minute intravenous infusion, followed every 3 weeks thereafter by a maintenance dose of 420 mg administered over a period of 30 to 60 minutes.
Anbefalet lopinavir/ritonavir dosis (mg) 2 gange daglig.
Recommended lopinavir/ritonavir dosing (mg) twice daily.
Anbefalet minimumsdosis er 10 mg/kg legemsvægt imidacloprid og 1,0 mg/kg legemsvægt moxidectin, svarende til 0,1ml/kg legemsvægt Advocate til katte.
The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 1.0 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight Advocate for cats.
Anbefalet minimumsdosis er 10 mg/kg legemsvægt imidacloprid og 2,5 mg/kg legemsvægt moxidectin, svarende til 0,1 ml/kg legemsvægt Advocate til hunde.
The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight Advocate for dogs.
Anbefalet minimumsdosis er 3 mg emodepsid/kg lgv og 12 mg praziquantel/kg lgv, hvilket svarer til 0,14 ml Profender /kg lgv.
The recommended minimum doses are 3 mg emodepside / kg body weight and 12 mg praziquantel / kg body weight, equivalent to 0.14 ml Profender / kg body weight.
Anbefalet plan
Recommended schedule
Anbefalet pædiatrisk dosering baseret på legemsoverfladeareal efter lead-in perioden
Recommended paediatric dosing by BSA after the lead-in period
Anbefalet revaccinationsprogram: Revaccination anbefales efter 1 år.
Recommended re-vaccination programme: Revaccination is recommended after 1 year.
Anbefalet separationsafstand c
Recommended separation distance c
Anbefalet skema for monitorering af nyrefunktion, med hensyntagen til tilstedeværelsen eller fraværet af yderligere risikofaktorer for nedsat nyrefunktion
Recommended schedule for monitoring renal function considering the presence or absence of additional risk factors for renal impairment
Anbefalet solvens til rekonstitution af Dynastat er:
Acceptable solvents for reconstitution of Dynastat are:
Anbefalet startdosis af ZYPADHERA
Recommended starting dose of ZYPADHERA
Anbefalet startdosis er 0,4 - 0,8 g/kg legemsvægt én gang efterfulgt af mindst 0,2 g/kg legemsvægt hver 3. til 4. uge.
The recommended starting dose is 0.4 - 0.8 g/kg given once, followed by at least 0.2 g/kg given every three to four weeks.
Anbefalet startdosis er 50 mg to gange daglig, hvilket bør øges efter en uge til en initial terapeutisk dosis på 100 mg to gange daglig.
The recommended starting dose is 50 mg twice a day which should be increased to an initial therapeutic dose of 100 mg twice a day after one week.
Anbefalet startdosis for EXJADE dispergible tabletter er 20 mg/kg kropsvægt.
The recommended initial daily dose of EXJADE dispersible tablets is 20 mg/kg body weight.
Anbefalet startdosis for EXJADE filmovertrukne tabletter er 14 mg/kg kropsvægt.
The recommended initial daily dose of EXJADE film-coated tablets is 14 mg/kg body weight.
Anbefalet startdosis ved CML i kronisk fase er 100 mg dasatinib 1 gang dagligt.
The recommended starting dose for chronic phase CML is 100 mg dasatinib once daily.
Anbefalet tidsplan for monitorering af nyrefunktionen under hensyntagen til forekomst eller manglende forekomst af yderligere risikofaktorer for nedsat nyrefunktion
Recommended schedule for monitoring renal function considering the presence or absence of additional risk factors for renal impairment
Anbefalet undersøgelsesprotokol
Recommended imaging protocol
Anbefaling af at monitorere patienterne for tegn og symptomer på neurotoksicitet
Recommendation to monitor patients for signs and symptoms of neurotoxicity
anbefaling af dosering ved
make dosing recommendations for
Anbefaling af en 3-timers observationsperiode på stedet efter injektion
Recommendation for a 3-hour on-site observation period post injection
Anbefaling af monitorering af patienterne for glucose, lipider og vægt.
Recommendations for monitoring of patients for glucose, lipids, and weight
Anbefaling af passende monitorering i tilfælde af at en hændelse skulle opstå, indtil hændelsen er forsvundet
Recommendation for appropriate monitoring until the event resolves if an event should occur
Anbefaling af, at det umiddelbart inden, patienten forlader sundhedscenteret, sikres, at patienten er bevidsthedsklar, kan orientere sig og er uden nogen tegn og symptomer på overdosering.
Recommendation that, immediately prior to a patient leaving the health care facility, it should be confirmed that the patient is alert, oriented, and absent of any signs or symptoms of overdose
Anbefaling af, at observationsperioden på 3 timer forlænges ud fra klinisk relevans for patienter, som udviser tegn eller symptomer forenelige med overdosering af olanzapin
Recommendation that the 3-hour observation period should be extended as clinically appropriate for patients who exhibit any signs or symptoms consistent with olanzapine overdose
Anbefaling af, at patienterne informeres om, at de resten af dagen efter en injektion ikke skal køre eller betjene maskiner, skal være opmærksomme på tegn og symptomer på et tilfælde af postinjektionssyndrom og skal kunne få hjælp om nødvendigt
Recommendation for informing patients that for the remainder of the day of the injection, they should not drive or operate machinery, should be vigilant for signs and symptoms of a post injection syndrome event, and should be able to obtain assistance if needed
Anbefaling af, at patienterne informeres om, at de resten af dagen efter en injektion ikke skal køre motorkøretøj eller betjene maskiner, skal være opmærksomme på tegn og symptomer på et tilfælde af postinjektionssyndrom og skal kunne få hjælp om nødvendigt
Recommendation for informing patients that for the remainder of the day of the injection, they should not drive or operate machinery, should be vigilant for signs and symptoms of a post injection syndrome event, and should be able to obtain assistance if needed
Anbefaling for monitorering natten over efter første dosis (eller når første-dosis-monitorering udføres ved genoptagelse af behandling)
Recommendation for overnight monitoring after the first dose (or if the first dose monitoring applies during treatment re-initiation)